Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 346 to 360 of 482 results for learning disabilities

  1. Violence and aggression: short-term management in mental health, health and community settings (NG10)

    This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under). It is relevant for mental health, health and community settings. The guideline aims to safeguard both staff and people who use services by helping to prevent violent situations and providing guidance to manage them safely when they occur.

  2. Visensia for early detection of deteriorating vital signs in adults in hospital (MIB36)

    NICE has developed a medtech innovation briefing (MIB) on Visensia for early detection of deteriorating vital signs in adults in hospital

  3. The PolySoft hernia patch used with the ONSTEP technique to treat inguinal hernias (MIB9)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Polysoft hernia patch for use with the ONSTEP technique to treat inguinal hernias

  4. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTE15)

    Early value assessment (EVA) guidance on virtual reality technologies for treating agoraphobia or agoraphobic avoidance....

  5. Smart One for measuring lung function (MIB96)

    NICE has developed a medtech innovation briefing (MIB) on Smart One for measuring lung function .

  6. Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)

    NICE has developed a medtech innovation briefing (MIB) on Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest .

  7. Fenfluramine for treating seizures associated with Dravet syndrome (TA808)

    Evidence-based recommendations on fenfluramine (Fintepla) for treating seizures associated with Dravet syndrome in people aged 2 and older.

  8. Ixekizumab for treating axial spondyloarthritis (TA718)

    Evidence-based recommendations on ixekizumab (Taltz) for treating axial spondyloarthritis in adults.

  9. Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)

    Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.

  10. Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

    NICE has developed a medtech innovation briefing (MIB) on Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions .

  11. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

  12. What training, support or interventions help to reduce caring-related accidents or incidents?

    confidence in caring, and their understanding of the health condition, disability or needs of the person they care for, so the committee...

  13. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services....

  14. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

  15. Nusinersen for treating spinal muscular atrophy (TA588)

    Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults.